- IFM to launch IFM Quattro, along with new incubator, IFM Discovery, and up to two additional subsidiaries focused on select targets of the innate immune system
- Financing is led by new investor Omega Funds, with participation from existing investors Atlas Venture and Abingworth
- Dr. Gary D. Glick to transition to role of executive chairman
Recent Press Releases
- Scorpion Therapeutics debuts with $108M to ‘put the sting in cancer’
- SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show
- Recombinetics Inc. Merges with Makana Therapeutics to Accelerate Xenotransplantation
- New technology to be commercialized by Vesigen Therapeutics for targeted intracellular drug delivery
- Arrakis, Roche team up on RNA-targeting drugs in $190M deal